PPAR regulation of inflammatory signaling in CNS diseases

PPAR Research

Volumn , Issue , 2008, Pages

  Bright, John J ^a,b   Kanakasabai, Saravanan ^a   Chearwae, Wanida ^a   Chakraborty, Sharmistha ^a  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; BEZAFIBRATE; CIGLITAZONE; FENOFIBRATE; GEMFIBROZIL; GW 7842; GW 784568; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; L 796449; LINOLEIC ACID; LIVER RECEPTOR HOMOLOG 1; NONSTEROID ANTIINFLAMMATORY AGENT; OLEIC ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PIRINIXIC ACID; PROSTACYCLIN; PROSTAGLANDIN J2; ROSIGLITAZONE; STAT PROTEIN; STEARIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ENCEPHALITIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 49749088893     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/658520     Document Type: Review

References (109)

1. Mustafa M. M., Ramilo O., Olsen K. D., Tumor necrosis factor in mediating experimental Haemophilus influenzae type B meningitis The Journal of Clinical Investigation 1989 84 4 1253 1259
2. Maffei C. M. L., Mirels L. F., Sobel R. A., Clemons K. V., Stevens D. A., Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis Infection and Immunity 2004 72 4 2338 2349
3. Dotis J., Roilides E., Immunopathogenesis of central nervous system fungal infections Neurology India 2007 55 3 216 220
4. Lucchinetti C., Brück W., Noseworthy J., Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment Current Opinion in Neurology 2001 14 3 259 269
5. Becher B., Bechmann I., Greter M., Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain Journal of Molecular Medicine 2006 84 7 532 543
6. Hemmer B., Archelos J. J., Hartung H.-P., New concepts in the immunopathogenesis of multiple sclerosis Nature Reviews Neuroscience 2002 3 4 291 301
7. Khan T. K., Alkon D. L., An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin Proceedings of the National Academy of Sciences of the United States of America 2006 103 35 13203 13207
8. Longo F. M., Massa S. M., Neuroprotective strategies in Alzheimer's disease Journal of the American Society of Experimental Neurotherapeutics 2004 1 1 117 127
9. Jones T., Ugalde V., Franks P., Zhou H., White R. H., Venous thromboembolism after spinal cord injury: incidence, time course, and associated risk factors in 16,240 adults and children Archives of Physical Medicine and Rehabilitation 2005 86 12 2240 2247
10. Jones T. B., Hart R. P., Popovich P. G., Molecular control of physiological and pathological T-cell recruitment after mouse spinal cord injury Journal of Neuroscience 2005 25 28 6576 6583
11. Wingerchuk D. M., Lucchinetti C. F., Noseworthy J. H., Multiple sclerosis: current pathophysiological concepts Laboratory Investigation 2001 81 3 263 281
12. Blumberg B., Evans R. M., Orphan nuclear receptors-new ligands and new possibilities Genes & Development 1998 12 20 3149 3155
13. Uppenberg J., Svensson C., Jaki M., Bertilsson G., Jendeberg L., Berkenstam A., Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ; The Journal of Biological Chemistry 1998 273 47 31108 31112
14. Shao D., Rangwala S. M., Bailey S. T., Krakow S. L., Reginato M. J., Lazar M. A., Interdomain communication regulating ligand binding by PPAR-γ; Nature 1998 396 6709 377 380
15. Kliewer S. A., Umesono K., Noonan D. J., Heyman R. A., Evans R. M., Convergence of 9- cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors Nature 1992 358 6389 771 774
16. Nolte R. T., Wisely G. B., Westin S., Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ; Nature 1998 395 6698 137 143
17. Janknecht R., Hunter T., A growing coactivator network Nature 1996 383 6595 22 23
18. Nuclear Receptors Nomenclature Committee, A unified nomenclature system for the nuclear receptor superfamily Cell 1999 97 2 161 163
19. Murakami K., Tobe K., Ide T., A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR- γ;. Effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats Diabetes 1998 47 12 1841 1847
20. Krey G., Braissant O., L'Horset F., Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay Molecular Endocrinology 1997 11 6 779 791
21. Peters J. M., Lee S. S. T., Li W., Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ) Molecular and Cellular Biology 2000 20 14 5119 5128
22. Saluja I., Granneman J. G., Skoff R. P., PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture Glia 2001 33 3 191 204
23. Polak P. E., Kalinin S., Dello Russo C., Protective effects of a peroxisome proliferator-activated receptor- β/ δ agonist in experimental autoimmune encephalomyelitis Journal of Neuroimmunology 2005 168 1-2 65 75
24. Pialat J.-B., Cho T.-H., Beuf O., MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice NMR in Biomedicine 2007 20 3 335 342
25. Harrington W. W., Britt C. S., Wilson J. G., The effect of PPARα, PPAR δ, PPAR γ;, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J Mice PPAR Research 2007 2007 13
26. Barak Y., Nelson M. C., Ong E. S., PPAR γ; is required for placental, cardiac, and adipose tissue development Molecular Cell 1999 4 4 585 595
27. Storer P. D., Xu J., Chavis J., Drew P. D., Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis Journal of Neuroimmunology 2005 161 1-2 113 122
28. Storer P. D., Xu J., Chavis J. A., Drew P. D., Cyclopentenone prostaglandins PGA2 and 15-deoxy-Δ12,14 PGJ2 suppress activation of marine microglia and astrocytes: implications for multiple sclerosis Journal of Neuroscience Research 2005 80 1 66 74
29. Dey D., Medicherla S., Neogi P., A novel peroxisome proliferator- activated gamma (PPAR γ;) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential Metabolism 2003 52 8 1012 1018
30. Natarajan C., Bright J. J., Peroxisome proliferator-activated receptor-gamma agonist inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation Genes & Immunity 2002 3 2 59 70
31. Diab A., Deng C., Smith J. D., Peroxisome proliferator-activated receptor- γ; agonist 15-deoxy-Δ12,14 -prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis The Journal of Immunology 2002 168 5 2508 2515
32. Feinstein D. L., Galea E., Gavrilyuk V., Peroxisome proliferator- activated receptor- γ; agonists prevent experimental autoimmune encephalomyelitis Annals of Neurology 2002 51 6 694 702
33. Storer P. D., Xu J., Chavis J., Drew P. D., Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis Journal of Neuroimmunology 2005 161 1-2 113 122
34. Niino M., Iwabuchi K., Kikuchi S., Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor- γ; Journal of Neuroimmunology 2001 116 1 40 48
35. Schmidt S., Moric E., Schmidt M., Sastre M., Feinstein D. L., Heneka M. T., Anti-inflammatory and antiproliferative actions of PPAR- γ; agonists on T lymphocytes derived from MS patients Journal of Leukocyte Biology 2004 75 3 478 485
36. Klotz L., Schmidt M., Giese T., Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor γ; levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients The Journal of Immunology 2005 175 8 4948 4955
37. Bright J. J., Natarajan C., Muthian G., Barak Y., Evans R. M., Peroxisome proliferator-activated receptor- γ; -deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis The Journal of Immunology 2003 171 11 5743 5750
38. Raikwar H. P., Muthian G., Rajasingh J., Johnson C. N., Bright J. J., PPAR γ; antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Δ12,14 -Prostaglandin J2 Journal of Neuroimmunology 2006 178 1-2 76 86
39. Rosenberg P. B., Clinical aspects of inflammation in Alzheimer's disease International Review of Psychiatry 2005 17 6 503 514
40. Hirohata M., Ono K., Naiki H., Yamada M., Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro Neuropharmacology 2005 49 7 1088 1099
41. McTigue D. M., Tripathi R., Wei P., Lash A. T., The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury Experimental Neurology 2007 205 2 396 406
42. Heneka M. T., Sastre M., Dumitrescu-Ozimek L., Acute treatment with the PPAR γ; agonist pioglitazone and ibuprofen reduces glial inflammation and A β1-42 levels in APPV717I transgenic mice Brain 2005 128 6 1442 1453
43. Watson G. S., Cholerton B. A., Reger M. A., Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study American Journal of Geriatric Psychiatry 2005 13 11 950 958
44. Wahner A. D., Bronstein J. M., Bordelon Y. M., Ritz B., Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease Neurology 2007 69 19 1836 1842
45. Casper D., Yaparpalvi U., Rempel N., Werner P., Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro Neuroscience Letters 2000 289 3 201 204
46. Wahner A. D., Bronstein J. M., Bordelon Y. M., Ritz B., Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease Neurology 2007 69 19 1836 1842
47. Dobrian D., Schriver S. D., Khraibi A. A., Prewitt R. L., Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity Hypertension 2004 43 1 18 56
48. Schütz B., Reimann J., Dumitrescu-Ozimek L., The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice Journal of Neuroscience 2005 25 34 7805 7812
49. Deplanque D., Cell protection through PPAR nuclear receptor activation Thérapie 2004 59 1 25 29
50. Culman J., Zhao Y., Gohlke P., Herdegen T., PPAR- γ;: therapeutic target for ischemic stroke Trends in Pharmacological Sciences 2007 28 5 244 249
51. Fujimoto S. T., Longhi L., Saatman K. E., McIntosh T. K., Motor and cognitive function evaluation following experimental traumatic brain injury Neuroscience & Biobehavioral Reviews 2004 28 4 365 378
52. Lee B.-C., Doo H.-K., Ahn S.-Y., Peroxisome proliferator-activated receptor- γ; Pro12Ala polymorphism is associated with the susceptibility to ischemic stroke in Taeeumin classified by Sasang medicine Neurological Research 2007 29 supplement 1 32 37
53. Allahtavakoli M., Shabanzadeh A. P., Sadr S. S., Parviz M., Djahanguiri B., Rosiglitazone, a peroxisome proliferator-activated receptor- γ; ligand, reduces infarction volume and neurological deficits in an embolic model of stroke Clinical and Experimental Pharmacology and Physiology 2006 33 11 1052 1058
54. Ou Z., Zhao X., Labiche L. A., Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPAR γ;) and 15d-prostaglandin J2 - mediated protection of brain after experimental cerebral ischemia in rat Brain Research 2006 1096 1 196 203
55. Zhao Y., Patzer A., Gohlke P., Herdegen T., Culman J., The intracerebral application of the PPAR γ; -ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain European Journal of Neuroscience 2005 22 1 278 282
56. Tureyen K., Kapadia R., Bowen K. K., Peroxisome proliferator-activated receptor- γ; agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents Journal of Neurochemistry 2007 101 1 41 56
57. Pereira M. P., Hurtado O., Cárdenas A., The nonthiazolidinedione PPAR γ; agonist L-796,449 is neuroprotective in experimental stroke Journal of Neuropathology & Experimental Neurology 2005 64 9 797 805
58. Nakamura T., Yamamoto E., Kataoka K., Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure Stroke 2007 38 11 3016 3022
59. Lincoff A. M., Wolski K., Nicholls S. J., Nissen S. E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials The Journal of the American Medical Association 2007 298 10 1180 1188
60. Dasgupta S., Roy A., Jana M., Hartley D. M., Pahan K., Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-α Molecular Pharmacology 2007 72 4 934 946
61. Deplanque D., Gelé P., Pétrault O., Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment The Journal of Neuroscience 2003 23 15 6264 6271
62. Collino M., Aragno M., Mastrocola R., Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-α agonist WY14643 Free Radical Biology and Medicine 2006 41 4 579 589
63. Besson V. C., Chen X. R., Plotkine M., Marchand-Verrecchia C., Fenofibrate, a peroxisome proliferator-activated receptor α agonist, exerts neuroprotective effects in traumatic brain injury Neuroscience Letters 2005 388 1 7 12
64. Gül Ş., Çelik S. E., Kalayci M., Taşyü rekli M., Çokar N., Bilge T., Dose-dependent neuroprotective effects of melatonin on experimental spinal cord injury in rats Surgical Neurology 2005 64 4 355 361
65. Haghighi S. S., Agrawal S. K., Surdell D. Jr., Effects of methylprednisolone and MK-801 on functional recovery after experimental chronic spinal cord injury Spinal Cord 2000 38 12 733 740
66. Polak P. E., Kalinin S., Dello Russo C., Protective effects of a peroxisome proliferator-activated receptor- β/ δ agonist in experimental autoimmune encephalomyelitis Journal of Neuroimmunology 2005 168 1-2 65 75
67. Iwashita A., Muramatsu Y., Yamazaki T., Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ -selective agonists in vitro and in vivo Journal of Pharmacology and Experimental Therapeutics 2007 320 3 1087 1096
68. Leonard J. P., Waldburger K. E., Goldman S. J., Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12 Journal of Experimental Medicine 1995 181 1 381 386
69. Bright J. J., Musuro B. F., Du C., Sriram S., Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis Journal of Neuroimmunology 1998 82 1 22 30
70. Cua D. J., Sherlock J., Chen Y., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 2003 421 6924 744 748
71. Szczuciński A., Losy J., Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies Acta Neurologica Scandinavica 2007 115 3 137 146
72. Sindern E., Role of chemokines and their receptors in the pathogenesis of multiple sclerosis Frontiers in Bioscience 2004 9 457 463
73. Glabinski A. R., Ransohoff R. M., Targeting the chemokine system for multiple sclerosis treatment Current Opinion in Investigational Drugs 2001 2 12 1712 1719
74. Muller D. M., Pender M. P., Greer J. M., Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis Current Drug Targets: Inflammation & Allergy 2004 3 3 279 290
75. Ukkonen M., Wu X., Reipert B., Dastidar P., Elovaara I., Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis Multiple Sclerosis 2007 13 6 701 707
76. Pershadsingh H. A., Heneka M. T., Saini R., Amin N. M., Broeske D. J., Feinstein D. L., Effect of pioglitazone treatment in a patient with secondary multiple sclerosis Journal of Neuroinflammation 2004 1, article 3 1 4
77. Redondo S., Ruiz E., Santos-Gallego C. G., Padilla E., Tejerina T., Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor- γ;, transforming growth factor- β1, and a Smad2-dependent mechanism Diabetes 2005 54 3 811 817
78. Shevach E. M., Chang J. T., Segal B. M., The critical role of IL-12 and the IL-12R β2 subunit in the generation of pathogenic autoreactive Th1 cells Springer Seminars in Immunopathology 1999 21 3 249 262
79. Segal B. M., Dwyer B. K., Shevach E. M., An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease Journal of Experimental Medicine 1998 187 4 537 546
80. Watford W. T., Hissong B. D., Bream J. H., Kanno Y., Muul L., O'Shea J. J., Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4 Immunological Reviews 2004 202 1 139 156
81. Touil T., Fitzgerald D., Zhang G.-X., Rostami A. M., Gran B., Pathophysiology of interleukin-23 in experimental autoimmune encephalomyelitis Drug News & Perspectives 2006 19 2 77 83
82. Veldhoen M., Hocking R. J., Atkins C. J., Locksley R. M., Stockinger B., TGF βin the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells Immunity 2006 24 2 179 189
83. Kamiya S., Owaki T., Morishima N., Fukai F., Mizuguchi J., Yoshimoto T., An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells The Journal of Immunology 2004 173 6 3871 3877
84. Gocke A. R., Cravens P. D., Ben L.-H., T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity The Journal of Immunology 2007 178 3 1341 1348
85. Collison L. W., Workman C. J., Kuo T. T., The inhibitory cytokine IL-35 contributes to regulatory T-cell function Nature 2007 450 7169 566 569
86. Wohlfert E. A., Nichols F. C., Nevius E., Clark R. B., Peroxisome proliferator-activated receptor γ; (PPAR γ;) and immunoregulation: enhancement of regulatory T cells through PPAR γ; -dependent and -independent mechanisms The Journal of Immunology 2007 178 7 4129 4135
87. Trinchieri G., Pflanz S., Kastelein R. A., The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses Immunity 2003 19 5 641 644
88. Ghosh S., May M. J., Kopp E. B., NF-κB and rel proteins: evolutionarily conserved mediators of immune responses Annual Review of Immunology 1998 16 225 260
89. Sha W. C., Regulation of immune responses by NF-κB/Rel transcription factors Journal of Experimental Medicine 1998 187 2 143 146. erratum in Journal of Experimental Medicine, vol. 187, no. 4, p. 661, 1998
90. Woronicz J. D., Gao X., Cao Z., Rothe M., Goeddel D. V., IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK Science 1997 278 5339 866 869
91. Murphy T. L., Cleveland M. G., Kulesza P., Magram J., Murphy K. M., Regulation of interleukin 12 p40 expression through an NF-κB half-site Molecular and Cellular Biology 1995 15 10 5258 5267
92. Mazzeo D., Panina-Bordignon P., Recalde H., Sinigaglia F., D'Ambrosio D., Decreased IL-12 production and Th1 cell development by acetyl salicylic acid-mediated inhibition of NF-κB European Journal of Immunology 1998 28 10 3205 3213
93. D'Ambrosio D., Cippitelli M., Cocciolo M. G., Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene The Journal of Clinical Investigation 1998 101 1 252 262
94. Grilli M., Memo M., Nuclear factor-κB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction Biochemical Pharmacology 1999 57 1 1 7
95. Mattson M. P., Camandola S., NF-κB in neuronal plasticity and neurodegenerative disorders The Journal of Clinical Investigation 2001 107 3 247 254
96. Migheli A., Piva R., Atzori C., Troost D., Schiffer D., c-Jun, JNK/SAPK kinases and transcription factor NF-κB are selectively activated in astrocytes, but not motor neurons, in amyotrophic lateral sclerosis Journal of Neuropathology & Experimental Neurology 1997 56 12 1314 1322
97. Dehmer T., Heneka M. T., Sastre M., Dichgans J., Schulz J. B., Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation Journal of Neurochemistry 2004 88 2 494 501
98. Jacobson N. G., Szabo S. J., Weber-Nordt R. M., Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4 Journal of Experimental Medicine 1995 181 5 1755 1762
99. Bacon C. M., Petricoin E. F. III, Ortaldo J. R., Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes Proceedings of the National Academy of Sciences of the United States of America 1995 92 16 7307 7311
100. Parham C., Chirica M., Timans J., A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R β1 and a novel cytokine receptor subunit, IL-23R The Journal of Immunology 2002 168 11 5699 5708
101. Aggarwal S., Ghilardi N., Xie M.-H., de Sauvage F. J., Gurney A. L., Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 The Journal of Biological Chemistry 2003 278 3 1910 1914
102. Murray P. J., The JAK-STAT signaling pathway: Input and output integration The Journal of Immunology 2007 178 5 2623 2629
103. O'Shea J. J., Park H., Pesu M., Borie D., Changelian P., New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway Current Opinion in Rheumatology 2005 17 3 305 311
104. Seidel H. M., Lamb P., Rosen J., Pharmaceutical intervention in the JAK/STAT signaling pathway Oncogene 2000 19 21 2645 2656
105. Bright J. J., Du D., Sriram S., Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis The Journal of Immunology 1999 162 10 6255 6262
106. Muthian G., Bright J. J., Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte Journal of Clinical Immunology 2004 24 5 542 552
107. Muthian G., Raikwar H. P., Rajasingh J., Bright J. J., 1,25 dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFN γ; axis leading to Th1 response in experimental allergic encephalomyelitis Journal of Neuroscience Research 2006 83 7 1299 1309
108. Natarajan C., Bright J. J., Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes The Journal of Immunology 2002 168 12 6506 6513
109. Lee T. L., Yeh J., Van Waes C., Chen Z., Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas Molecular Cancer Therapeutics 2006 5 1 8 19